Lilly Asia Ventures
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's Transcenta secures $100m funding round
Transcenta Holding, a Chinese biotech company formed last year through the merger of MabSpace Bioscience and Hangzhou Just Biotherapeutics (HJB), has raised $100 million in an extended Series B funding round.
Chinese genetic testing player secures $115m round
Geneseeq, a Chinese genetic testing company that focuses on treatments for cancer, has raised RMB800 million ($115 million) in a funding round led by state-owned China Reform Holding Corporation.
Chinese biopharma player secures $100m Series B
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
China's KeChow Pharma gets $45m Series C
Shanghai Kechow Pharma, a Chinese small molecule targeted drug developer, has raised a $45 million Series C round led by Decheng Capital.
Chinese medical device start-up receives $100m
Chinese medical instrument provider Peijia Medical has raised a RMB700 million ($100 million) Series C round from a group including Matrix Partners China and Lilly Asia Ventures.
Goldman leads $62m Series D for China's Fountain Medical
Fountain Medical Development, a China-based contract research organization (CRO) that serves a global client base of drug developers, has received $62 million in Series D funding led by Goldman Sachs.
Qiming leads $37m round for Hong Kong biotech player
Qiming Venture Partners has led a $37 million Series B round for Insilico Medicine, a Hong Kong-based drug development company that uses artificial intelligence (AI).
Women on corporate boards: Finding a voice
Investor pressure and industry lobbying has contributed to a rise in female representation on corporate boards. While quotas work for some, they aren’t necessarily the silver bullet
Women in PE: Mind the gap
Gender diversity within private equity is an increasing priority for LPs and GPs alike. Addressing problems around the recruitment and retention of women requires fundamental changes in culture and mindset
Qiming leads $42m Series B for China cancer drug developer
Qiming Venture Partners has led a $42 million Series B round for Chinese cancer drug developer Abbisko.
Advantech, CMBI lead Series C for China's InventisBio
Advantech Capital and CMB International, an investment unit of China Merchants Bank, have led a $70 million Series C funding round for InventisBio, a Chinese clinical stage biotech company.
Lilly Asia Ventures closes Fund V at $750m hard cap
Lilly Asia Ventures (LAV) has closed its fifth healthcare fund – which operates globally but primarily backs companies with a China angle – at the hard cap of $750 million. It represents a meaningful step up in size from the $450 million raised for...
GIC leads $125m round for China cancer diagnostics business
GIC Private has led a RMB850 million ($125.5 million) Series C round for Burning Rock, a Chinese cancer diagnostics start-up that is already working with hospitals on products based on DNA sequencing analysis.
IDG, Lilly join $10m round for China’s EdiGene
IDG Capital and Lilly Asia Ventures (LAV) have joined a $10 million investment in EdiGene, a developer of genetics-based therapies based in Beijing.
Hillhouse co-leads $93m Series B for US biotech firm
Hillhouse Capital and Quan Capital have led a $93 million Series B round for NextCure, a US-based biopharmaceutical company focused on cancer and other diseases.
Innovent Biologics gains on debut after $421m IPO
Chinese cancer drug developer Innovent Biologics, which has a number of PE backers, closed up on its Hong Kong trading debut, following a HK$3.3 billion ($421 million) IPO.
US, China-based Terns Pharma secures $80m Series B
Vivo Capital and Orbimed have co-led an $80 million Series B funding round for US and China-based Terns Pharmaceuticals.
Decheng leads Series C for China's Impact Therapeutics
Chinese biopharmaceuticals developer Impact Therapeutics has raised $30 million in Series C funding from a group of investors led by Decheng Capital.
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
Drug developer Just China raises $35m
Hangzhou Just Biotherapeutics (Just China), the Chinese joint venture of US drug developer Just Biotherapeutics, has received $35 million in Series B-plus funding led by Hillhouse Capital.
Sequoia leads $40m round for Hong Kong biotech player
Sequoia Capital China has led a $40 million Series B round of funding for MabSpace Bioscience, a Hong Kong-headquartered drug developer that specializes in cancer treatments.
Lilly Asia leads $25m round for US-based Avedro
Lilly Asia Ventures (LAV) has led a $25 million round for Avedro, a US-based ophthalmic pharmaceutical and medical devices company with a view to expanding in Asia.
Capital Group leads Series E for China’s Innovent Biologics
Capital Group Private Markets (CGPM), a private equity affiliate of US-based Capital Group Companies, has led a $150 million Series E round for Chinese biopharmaceutical developer Innovent Biologics.